Galena Biopharma (GALE) Tops Q3 EPS by 6c

Galena Biopharma (NASDAQ: GALE) reported Q3 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.66 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• Stardust Power (SDST) Tops Q2 EPS by 1c